227 related articles for article (PubMed ID: 14871958)
1. Vaccination of cancer patients against telomerase induces functional antitumor CD8+ T lymphocytes.
Vonderheide RH; Domchek SM; Schultze JL; George DJ; Hoar KM; Chen DY; Stephans KF; Masutomi K; Loda M; Xia Z; Anderson KS; Hahn WC; Nadler LM
Clin Cancer Res; 2004 Feb; 10(3):828-39. PubMed ID: 14871958
[TBL] [Abstract][Full Text] [Related]
2. Antitumor effect of new multiple antigen peptide based on HLA-A0201-restricted CTL epitopes of human telomerase reverse transcriptase (hTERT).
Liao ZL; Tang XD; Lü MH; Wu YY; Cao YL; Fang DC; Yang SM; Guo H
Cancer Sci; 2012 Nov; 103(11):1920-8. PubMed ID: 22909416
[TBL] [Abstract][Full Text] [Related]
3. Immunization of patients with the hTERT:540-548 peptide induces peptide-reactive T lymphocytes that do not recognize tumors endogenously expressing telomerase.
Parkhurst MR; Riley JP; Igarashi T; Li Y; Robbins PF; Rosenberg SA
Clin Cancer Res; 2004 Jul; 10(14):4688-98. PubMed ID: 15269141
[TBL] [Abstract][Full Text] [Related]
4. Targeting human telomerase reverse transcriptase with recombinant lentivector is highly effective to stimulate antitumor CD8 T-cell immunity in vivo.
Adotévi O; Mollier K; Neuveut C; Dosset M; Ravel P; Fridman WH; Tartour E; Charneau P; Wain-Hobson S; Langlade-Demoyen P
Blood; 2010 Apr; 115(15):3025-32. PubMed ID: 20130242
[TBL] [Abstract][Full Text] [Related]
5. Characterization of HLA-A3-restricted cytotoxic T lymphocytes reactive against the widely expressed tumor antigen telomerase.
Vonderheide RH; Anderson KS; Hahn WC; Butler MO; Schultze JL; Nadler LM
Clin Cancer Res; 2001 Nov; 7(11):3343-8. PubMed ID: 11705846
[TBL] [Abstract][Full Text] [Related]
6. Human telomerase reverse transcriptase-specific T-helper responses induced by promiscuous major histocompatibility complex class II-restricted epitopes.
Schroers R; Shen L; Rollins L; Rooney CM; Slawin K; Sonderstrup G; Huang XF; Chen SY
Clin Cancer Res; 2003 Oct; 9(13):4743-55. PubMed ID: 14581345
[TBL] [Abstract][Full Text] [Related]
7. Immunogenic HLA-B*0702-restricted epitopes derived from human telomerase reverse transcriptase that elicit antitumor cytotoxic T-cell responses.
Adotévi O; Mollier K; Neuveut C; Cardinaud S; Boulanger E; Mignen B; Fridman WH; Zanetti M; Charneau P; Tartour E; Lemonnier F; Langlade-Demoyen P
Clin Cancer Res; 2006 May; 12(10):3158-67. PubMed ID: 16707616
[TBL] [Abstract][Full Text] [Related]
8. Generation in vivo of peptide-specific cytotoxic T cells and presence of regulatory T cells during vaccination with hTERT (class I and II) peptide-pulsed DCs.
Aloysius MM; Mc Kechnie AJ; Robins RA; Verma C; Eremin JM; Farzaneh F; Habib NA; Bhalla J; Hardwick NR; Satthaporn S; Sreenivasan T; El-Sheemy M; Eremin O
J Transl Med; 2009 Mar; 7():18. PubMed ID: 19298672
[TBL] [Abstract][Full Text] [Related]
9. Telomerase mRNA-transfected dendritic cells stimulate antigen-specific CD8+ and CD4+ T cell responses in patients with metastatic prostate cancer.
Su Z; Dannull J; Yang BK; Dahm P; Coleman D; Yancey D; Sichi S; Niedzwiecki D; Boczkowski D; Gilboa E; Vieweg J
J Immunol; 2005 Mar; 174(6):3798-807. PubMed ID: 15749921
[TBL] [Abstract][Full Text] [Related]
10. Differential lysis of tumors by polyclonal T cell lines and T cell clones specific for hTERT.
Chen DY; Vance BA; Thompson LB; Domchek SM; Vonderheide RH
Cancer Biol Ther; 2007 Dec; 6(12):1991-6. PubMed ID: 18087213
[TBL] [Abstract][Full Text] [Related]
11. Diepitope multiple antigen peptide of hTERT trigger stronger anti-tumor immune responses in vitro.
Liao ZL; Luo G; Xie X; Tang XD; Bai JY; Guo H; Yang SM
Int Immunopharmacol; 2013 Aug; 16(4):444-50. PubMed ID: 23714071
[TBL] [Abstract][Full Text] [Related]
12. In vitro quantification of the cytotoxic T lymphocyte response against human telomerase reverse transcriptase in breast cancer.
Amarnath SM; Dyer CE; Ramesh A; Iwuagwu O; Drew PJ; Greenman J
Int J Oncol; 2004 Jul; 25(1):211-7. PubMed ID: 15202008
[TBL] [Abstract][Full Text] [Related]
13. Uses of telomerase peptides in anti-tumor immune therapy.
Li H; Katik I; Liu JP
Methods Mol Biol; 2007; 405():61-86. PubMed ID: 18369818
[TBL] [Abstract][Full Text] [Related]
14. Enhanced antitumor effect against human telomerase reverse transcriptase (hTERT) by vaccination with chemotactic-hTERT gene-modified tumor cell and the combination with anti-4-1BB monoclonal antibodies.
Lin X; Zhou C; Wang S; Wang D; Ma W; Liang X; Lin C; Wang Z; Li J; Guo S; Zhang Y; Zhang S
Int J Cancer; 2006 Oct; 119(8):1886-96. PubMed ID: 16708388
[TBL] [Abstract][Full Text] [Related]
15. Myeloid dendritic cells loaded with dendritic tandem multiple antigenic telomerase reverse transcriptase (hTERT) epitope peptides: a potentially promising tumor vaccine.
Niu BL; Du HM; Shen HP; Lian ZR; Li JZ; Lai X; Wei SD; Zou LQ; Gong JP
Vaccine; 2012 May; 30(23):3395-404. PubMed ID: 22480929
[TBL] [Abstract][Full Text] [Related]
16. Artificial antigen-presenting cells transduced with telomerase efficiently expand epitope-specific, human leukocyte antigen-restricted cytotoxic T cells.
Dupont J; Latouche JB; Ma C; Sadelain M
Cancer Res; 2005 Jun; 65(12):5417-27. PubMed ID: 15958591
[TBL] [Abstract][Full Text] [Related]
17. Lack of tumor recognition by hTERT peptide 540-548-specific CD8(+) T cells from melanoma patients reveals inefficient antigen processing.
Ayyoub M; Migliaccio M; Guillaume P; Liénard D; Cerottini JC; Romero P; Lévy F; Speiser DE; Valmori D
Eur J Immunol; 2001 Sep; 31(9):2642-51. PubMed ID: 11536162
[TBL] [Abstract][Full Text] [Related]
18. Cytotoxic T cell responses to human telomerase reverse transcriptase in patients with hepatocellular carcinoma.
Mizukoshi E; Nakamoto Y; Marukawa Y; Arai K; Yamashita T; Tsuji H; Kuzushima K; Takiguchi M; Kaneko S
Hepatology; 2006 Jun; 43(6):1284-94. PubMed ID: 16729333
[TBL] [Abstract][Full Text] [Related]
19. Interferon-gamma differentially regulates susceptibility of lung cancer cells to telomerase-specific cytotoxic T lymphocytes.
Tajima K; Ito Y; Demachi A; Nishida K; Akatsuka Y; Tsujimura K; Hida T; Morishima Y; Kuwano H; Mitsudomi T; Takahashi T; Kuzushima K
Int J Cancer; 2004 Jun; 110(3):403-12. PubMed ID: 15095306
[TBL] [Abstract][Full Text] [Related]
20. gp100(209-2M) peptide immunization of human lymphocyte antigen-A2+ stage I-III melanoma patients induces significant increase in antigen-specific effector and long-term memory CD8+ T cells.
Walker EB; Haley D; Miller W; Floyd K; Wisner KP; Sanjuan N; Maecker H; Romero P; Hu HM; Alvord WG; Smith JW; Fox BA; Urba WJ
Clin Cancer Res; 2004 Jan; 10(2):668-80. PubMed ID: 14760090
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
